Trastuzumab wins backing of European drug regulatorBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7549.1050 (Published 04 May 2006) Cite this as: BMJ 2006;332:1050
- Clare Dyer, legal correspondent
Trastuzumab (Herceptin), the breast cancer drug at the centre of a row over rationing in the NHS, last week won the first stage of approval by the European drug regulator for use in treating early stage cancer.
A committee of the European Medicines Agency, which licenses drugs for European Union countries, backed the extension of the drug's licence to include early stage disease in a record 10 weeks from application.
The recommendation, from the agency's committee for medicinal products for human use, is for the use of trastuzumab after surgery and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial